sessions bio-europe springevents.ebdgroup.com/bes/core/downloads/2019/bes 2019 agenda.pdf · their...

COURSE 1: The Negotiation Masterclass –Improving The Probability of Success

08:00 - 17:00EBD Academy: COURSE 1

// ADDITIONAL REGISTRATION FEE //

The Negotiation Masterclass – Improving TheProbability of Success takes place on March 23 -24 ,Vienna, Austria ahead of BIO-Europe Spring. It is aninteractive two-day workshop for businessdevelopment professionals who want to becomestrong and successful negotiators in high valuenegotiations.

LEARN MORE »

SESSIONSPRE-EVENT PROGRAMS - 23/03/2019

BIO-Europe SpringMarch 25–27, 2019

Messe Wien Exhibition and Congress CenterVienna, Austria

+49 89 2388 756 0 ebdgroup.knect365.com/bioeurope-spring/ [email protected]

https://ebdgroup.knect365.com/negotiation-masterclass/

TIME EBD ACADEMY: COURSE 1

08:00 08:00 - COURSE 1: The Negotiation Masterclass – Improving The Probability of Success

SCHEDULEPRE-EVENT PROGRAMS - 23/03/2019




COURSE 1 Continued: The NegotiationMasterclass – Improving The Probability ofSuccess



The Negotiation Masterclass – Improving TheProbability of Success takes place on March 23 -24 ,Vienna, Austria ahead of BIO-Europe Spring. It is aninteractive two-day workshop for businessdevelopment professionals who want to becomestrong and successful negotiators in high valuenegotiations.

LEARN MORE »

COURSE 2: Product Valuation & DealStructuring Masterclass



The Product Valuation & Deal Structuring Masterclasstakes place on March 24, Vienna, Austria ahead ofBIO-Europe Spring. It is an intensive one-day workshopfor business development professionals who want tomaximize their product valuation and deal structuringskills to gain a competitive advantage whennegotiating a deal.

LEARN MORE »

EUROPE CEO

09:00 - 19:00Leading Biotech

Stay at the forefront of European biotechdevelopments in an intimate setting unlike anotherother

REQUEST YOUR EXCLUSIVE INVITATION

Registration open

14:00 - 19:00Main Agenda

Level 0, Foyer A

Registration open (at the conference center) - Pick upname badges

Welcome Reception

19:00 - 21:00Networking

LOCATION:Vienna City HallFriedrich-Schmidt-Platz 1Entrance: Lichtenfelsgasse 2Feststiege 11010 Vienna

All BIO-Europe Spring attendees are cordially invited tojoin us for the welcome reception. You will be able topick up your name badge at the welcome receptionbetween 19:00-21:00.

Friedrich von Schmidt designed and built Vienna's CityHall, the most important secular building in the neo-Gothic style in the city, between 1872 and 1883. It isthe official seat of the Mayor and the meeting place ofthe city senate/provincial government and theMunicipal Council/Landtag.

The City Hall is a building of superlatives: The heightof the tower is 97.9 m, plus the so-called "IronRathausmann," which has become a symbol of Vienna.Over 30 million bricks and more than 40,000 cubicmeters of natural stone were used. The Arkadenhof ofCity Hall is one of the biggest inner courtyards inEurope, and Festival Hall is 71 meters long, 20 meterswide and 18.5 meters high. If the fire authorities wereto allow it, 1,500 couples could dance the waltz here atthe same time.

SESSIONSPRE-EVENT PROGRAMS - 24/03/2019




https://ebdgroup.knect365.com/negotiation-masterclass/

https://ebdgroup.knect365.com/product-valuation-business-development-masterclass/

https://get.knect365.com/leadingbiotech-europeceo2019/?_ga=2.101957126.661180911.1548687364-172062442.1541002328

TIME EBD ACADEMY: COURSE 1 EBD ACADEMY: COURSE 2 LEADING BIOTECH MAIN AGENDA NETWORKING

08:00 08:00 - COURSE 1 Continued: The Ne-gotiation Masterclass – ImprovingThe Probability of Success

08:30 - COURSE 2: Product Valuation& Deal Structuring Masterclass

09:00 09:00 - EUROPE CEO

10:00

11:00

12:00

13:00

14:00 14:00 - Registration open

15:00

16:00

17:00

18:00

19:00 19:00 - Welcome Reception

SCHEDULEPRE-EVENT PROGRAMS - 24/03/2019




Registration and Exhibition Open


Registration Location: Level 0, Foyer A

Exhibition Location: Level 0, Hall A

Please note: The registration desk will be open all day.

Continental Breakfast


Level 0, Hall A

The perfect pitch: Do you have what it takes towin over investors?

09:00 - 10:00WORKSHOP 1

Level 1, Schubert 4

What you have to say in 30 seconds could mean thedifference between a meeting with an investor and adoor closed in your face. Win a one-to-one meetingwith a leading life science private equity investor.Members of the audience will have 30 seconds to givetheir elevator pitch to a star-studded panel ofseasoned industry investors. The top picks will beselected for a second round that includes two minutesof presentation and/or Q&A time with the judges. First-and second-place winners will receive a full 30-minuteprivate follow-up meeting with the panelist of theirchoice. Judges will receive a written summary of allparticipant pitches and their scores, should they wishto follow up on their own. All are welcome:entrepreneurs, service providers, job seekers,executives and more. Audience preparation notes:Participants will be judged on the quality andeffectiveness of the overall 30-second pitch.Remember, the primary goal of an elevator pitch is tospark interest for a follow-up meeting. Pre-workshopcoaching is available from the moderator (contact:[email protected]). Practice, practice, practice!

Participants

Moderator: Douglas MacDougall - Managing Partner,MacDougall Biomedical Communications

Panelist: Jasper Bos - Senior VP and ManagingDirector, M Ventures

Panelist: Roel Bulthuis - Managing Director, INKEFCapital

Panelist: Tim Haines - Managing Partner, Abingworth

Panelist: Christian Jung - Principal, WellingtonPartners Life Sciences

Panelist: Mathieu Pieronne - Investment Manager,Andera Partners

Panelist: Elizabeth Roper - Partner, Epidarex Capital

EBD Academy Buzz Session: Out-licensingpresentations: One is not enough

09:00 - 09:45WORKSHOP 2

Level 1, Schubert 6

Effective communication is one of the most importantfactors associated with successful out-licensingstrategies. It is vital in securing you meetings,conveying your message and outlining your aims.However, too many company executives try (and oftenfail) to secure meetings with prospective licensingpartners, in part because their communications(presentations, meeting request text, emails, etc.) arepoorly designed, poorly written, and rarely customized.

In this buzz session, we will focus on how to craft out-licensing presentations that communicate effectively.Topics covered during this presentation include:• Why more than one presentation is necessary• The number and structure of these out-licensingpresentations• Outlines and examples of each kind ofpresentation...and when to use them• How to craft meeting text that increases yourchances of a meeting at a conference• Why "crosschecking" is critical for starting yourpartnering activities early

Attendees will leave this session with acomprehensive understanding of how out-licensingpresentations should be developed, structured anddelivered. After attending, you will increase yourchances of securing meetings with potential partnersat licensing conferences and beyond.

Participants

Moderator: Carlos N. Velez - Founder and ManagingPartner, Lacerta Bio BD&L

One-to-one meetings

10:00 - 18:30Partnering

Level 0, Hall A

Please note: One-to-one meetings will take place allday depending on your partnering schedule.

Power up partneringONE: Essentials (plusExperienced)

10:00 - 10:45Power up partneringONE

Level 1, Business Suite 1

This session is for delegates new to partnering. Whatcan you expect from partnering, and what do othersexpect from you? Principles around timing, humannature, and partnering etiquette will be applied to thepartneringONE process. The first 30 minutes will giveyou a clear understanding of tactics to generate thebest ROI from partnering, at this and future events.

Those who stay for the full session will also hear thecontent from the Power up: Experienced session. Thesecond half will cover methods for collaborating withcolleagues, saving time, increasing response rates andacceptance rates, based on leveragingpartneringONE’s new power features.

This session is being offered multiple times duringBIO-Europe Spring. Each session is limited to 20people. Please reserve your seat by adding the sessionto your personal agenda. If you can’t attend a session,drop by the partnering help desk with any questions.

Participants

Speaker: Lisa Methley - Senior Director, OnlineStrategy, EBD Group

Welcome and Opening Remarks

10:45 - 11:15Plenary

Level 0 - Lehar 3/4

Participants

Speaker: Pam Putz - Managing Director Europe, EBDGroup

Speaker: Margarete Schramböck - The Minister,Federal Ministry for Digital and Economic Affairs

Speaker: Peter Hanke - Executive City Councillor ofFinance, Business, Digital Innovation and InternationalAffairs, City of Vienna

Speaker: David Thomas - Senior Director, IndustryResearch and Analysis, Biotechnology InnovationOrganization (BIO)

SESSIONSDAY 1 - 25/03/2019




Opening Plenary Discussion: Time to turn theship: Exploring underserved therapeutic areas

11:15 - 12:15Plenary

Level 0, Lehar 3/4

Therapeutic areas outside of oncology, chronicdiseases and CNS spaces tend to be afterthoughts inmany discussions about biotech growth. Underservedtherapeutic areas offer exciting possibilities for futuredevelopment however. These spaces are characterizednot only by small patient populations but also bypatients with poor access to healthcare, bymismatched financial incentives, and high incidence inunfamiliar areas of operation. Often, these areas havesome combination of all four of these features and sodifferent kinds of partnerships and development plansare required. This panel will identify the topunderserved therapeutic areas, explore some of thecurrent efforts to address them and the partnershipsthat are proving to be effective. The panelists willaddress potential areas of future growth and whatneeds to happen in the industry, through policy,research, and funding to bring biotech solutions tounderserved therapeutic areas.

Participants

Moderator: Amy Schulman - Partner, Polaris Partners

Panelist: Michael Crowley - Head, BD for PharmaResearch and Early Development, Roche PharmaPartnering

Panelist: Danielle Friend - Director, Science andRegulatory Affairs, Biotechnology InnovationOrganization (BIO)

Panelist: David Rossow - Founding Partner, StrategicInvestment Fund, Bill & Melinda Gates Foundation

Panelist: Jonathan Wang - VP, Head of BusinessDevelopment, Zai Lab

Luncheon


Seated Luncheon – Level 0, MallGrab & Go Lunch – Level 0, Hall A

Who wins the seat when investing in Europeanbiotech companies?

13:30 - 14:30Business Development

Level 1, Schubert 1/2

Participants

Moderator: Annegret de Baey-Diepolder - VenturePartner, Life Sciences Department, Seventure Partners

Panelist: Roel Bulthuis - Managing Director, INKEFCapital

Panelist: Laia Crespo - Head of Europe, SanofiVentures

Bruno Montanari - Partner, Seroba Life Sciences

Panelist: Gilles Nobécourt - Partner, Andera Partners

Evolving biopharma landscape in the Asia-Pacific

13:30 - 14:30Spotlight

Level 1, Schubert 4

The 21st century goldrush: With record-breaking dealsin the past two years, partnering and investmentopportunities in the APAC region continue to attractopportunists seeking their fortunes in the biopharmasector. Novel business models are being developed tocreate efficient ways to fund and develop innovativetechnologies and new products at a rate neverwitnessed before. How are companies, investors,accelerators, and other stakeholders working togetherto advance the field? What cross-border opportunitiesare enabling treatments to be developed more quicklyand more broadly? Organizations that are breaking themold and cashing in on the new opportunities sharetheir strategies for success.

Participants

Moderator: Robert Narquizian - Managing Director,ChinaBio® Group

Panelist: Nares Damrongchai - CEO, Thailand Centerof Excellence for Life Sciences

Panelist: Amy Nguyen - Head, Business Development,GreenLight Clinical

Panelist: Rajan Puri - Head, Business DevelopmentNorth America, CMAB Biopharma

Emerging opportunities for investment andpartnering in “metabesity”

13:30 - 14:30Therapeutic

Level 1, Schubert 5

Despite increases in life expectancy over the lastcentury, healthspan—time spent living without chronicdisease—has not significantly increased and remains adriver of immense personal and economic costs.Growing evidence has linked common metabolic rootsto the aging process and multiple chronic diseases,collectively referred to as metabesity. Presently,targeting metabesity indications requires first pursuingestablished gateway indications—T2DM, obesity and,more recently, NASH, all of which come with their owndevelopment, regulatory and market accesschallenges. Nevertheless, a new wave of biotechcompanies with promising assets is targetinghealthspan and other metabesity indications. A widevariety of strategies are being used: pursuing initialorphan indications, novel efficacy composites, andadvanced computational tools, including artificialintelligence. Join our panel as we discuss prospectsand opportunities for investing and partnering inmetabesity programs.

Participants

Moderator: Danielle M. Marra - Associate Principal,Cello Health BioConsulting

Panelist: Sree Kant - Head, Business Development,Life Biosciences

Panelist: Tomas Landh - Innovation Sourcing VP,Senior Principal Scientist, Novo Nordisk

Panelist: Thomas Seoh - President and CEO, Kinexum





Pharma Company Presentations

13:30 - 17:00Company Presentations

Level 0, Lehar 3/4

14:00–14:15 – Bristol-Myers Squibb – Paul Biondi,Senior Vice President, Strategy and BusinessDevelopment

14:15–14:30 – Roche Pharma Partnering – J.C.Lopez, Business Development Associate

14:30–14:45 – Bayer – Christoph Geserick, Director,Early Licensing & Transactions

14:45–15:00 – Johnson & Johnson Innovation –Guenter Huhle, Head of JLABS EMEA

15:00–15:15 – AbbVie – Joachim Vogt, DirectorSearch & Evaluation Western Europe

15:15–15:30 – Sanofi – Olivier Reinhard, Head ofBusiness Development & Licensing Transactions –China & Emerging Markets

15:30–15:45 – MSD – Phil L’Huillier, Head of BusinessDevelopment, Europe & Middle East

15:45–16:00 – Amgen – Samantha Palmer, Director,Business Development

16:00–16:15 – Eli Lilly and Company – JohnstonErwin, Vice President, Corporate BusinessDevelopment

16:15–16:30 – Boehringer Ingelheim – Dr. GuidoBoehmelt, Director External Innovation, ResearchBeyond Borders and Silke Hobbie, Global Head ofRespiratory Business Development & Licensing

16:30–16:45 – Merck – Philippe Lopes-Fernandes,SVP, Global Head of Business Development & AllianceManagement

16:45–17:00 – Servier – Didier Landais, Global Headof Licensing

Art of multitrack deal: Keys to maximizing thevalue of your company



Pursuing multiple deal options in parallel will createthe kind of competitive tension that will enable acompany to achieve the fullest value for an asset orthe company itself, whether the end result of thatprocess is an asset sale, global or regionalpartnership, new round of investment, or M&A. Learnwhich companies can benefit from a multi-track, howto time the components, and how to position for apositive outcome.

Participants

Moderator: Lubor Gaal - Senior VP, Head of Europe,Locust Walk

Panelist: Hubert Birner - Managing Partner, TVMCapital Life Science

Panelist: Timothy Herpin - Chief Business Officer,Caribou Biosciences

Panelist: Jennifer Laird - VP, Search and Evaluation,Neuroscience, Eli Lilly and Company

Panelist: Øystein Soug - CEO, Targovax

Product development and market access: Thetransformational changes within China


Level 1, Schubert 4

The Asia Pacific region represents more than 50% ofthe world’s population, one that needs to address itsproliferation of common Western chronic diseases, aquickly expanding aging society, and health conditionsunique to the area. This presents significantopportunities for companies that are able to meet theneeds of these diverse patient groups. We will discusshow China’s new economy biotechs are able toleverage the increasingly supportive regulatoryenvironment, the large and hungry investor base, andthe maturing ecosystem? What strategies are beingused to gain access to this market that simultaneouslyrepresents developed and emerging markets? How arethe players mastering regional and global markets?Leaders in this field share their insights on the bestways to navigate this evolving landscape.

Participants

Moderator: Debra Yu - Managing Director, ChinaRenaissance

Panelist: Jun Bao - President and CEO, IMPACTTherapeutics

Panelist: Jay Mei - Chairman and CEO, Antengene

Panelist: John Xu - CEO and Cofounder, JemincareTherapeutics Corp

Panelist: Jonathan Zhao - Executive Chairman,Transcenta

What’s NEXT in NASH?


Level 1, Schubert 5

NASH is fast growing into a global epidemic and isgoing to become the leading cause of liver transplantswith the number of transplantable organs nowhereclose to meeting this future demand. Will the industrysucceed to deliver treatments for an emerging NASHpandemic in time? Europe, the US and Asia havebrought forth a number of players in the space withabout 195 treatments in the pipeline but currentlythere are no approved therapies and the lion's share ofprograms target the early stages of NASH. The marketis pegged to hit $25 billion by 2026 for the truewinners of this race—first in class and best in classapproaches—to take. This panel will look at what isnext to come in NASH and what will truly make adifference in this devastating illness in the long run.

Participants

Moderator: Mario Brkulj - VP, MacDougall BiomedicalCommunications

Panelist: Manuel Baader - Deputy Head of GlobalBD&L, CardioMetabolic Diseases, BoehringerIngelheim

Panelist: Marco Boorsma - General Partner, Forbion

Panelist: Pascale Jordan - Director, BusinessDevelopment, External Evaluation, PrometheraBiosciences

Panelist: Tuan Huy Nguyen - Chairman and ChiefScientific Officer, GoLiver Therapeutics

Towards the splendid city: Creating world-leading biotech companies in Europe



Participants

Moderator: Vanela Bushi - Director, Strategy andTransactions, Syneos Health Consulting

Panelist: Regina Hodits - General Partner, WellingtonPartners Life Sciences

Panelist: Peter B. Leone - Chief Business Officer,Bicycle Therapeutics

Panelist: Nerida Scott - VP, New Ventures andTransactions, Johnson & Johnson Innovation

Panelist: Jeff Wasserstein - Managing Director,Greenhill & Co.





Commercial opportunities and challenges incell and gene: The keys to success


Level 1, Schubert 4

As clinical advances continue to be made and newtreatments and potential cures are being developed,how can we ensure that patients will have access tothese life-changing products? How are companiesworking together with government agencies toaddress regulatory, market access, and pricing issues?How are new guidelines such as RMAT designationfacilitating the approval of new drugs? What types ofnovel pricing models are being developed to addressthe high costs of these products? Industry experts willdiscuss the new paths available for bringing theseadvanced therapies to market.

Participants

Moderator: Paolo Morgese - Director, EU MarketAccess and Member Relations, Alliance forRegenerative Medicine (ARM)

Panelist: Jeff Abbey - CEO, Novadip Biosciences

Panelist: Becky Buzzeo - Senior Director, GlobalBusiness Development - Biologics, Thermo FisherScientific, Pharma Services

Panelist: Roman Necina - Chief StrategistPharmaceutical Sciences, Takeda

Panelist: Peter Nell - VP, Strategy and BusinessDevelopment, Casebia Therapeutics

Oncology positioning and partneringstrategies: IO, non-IO, and everything inbetween!


Level 1, Schubert 5

The clinical and commercial impact of anticancerimmunotherapies cannot be overstated: Durableremissions in subsets of end-stage patients withimmune checkpoint inhibitors and CAR-T therapies,and the ensuing influx of investment and partneringactivity, have been astounding. With the dust startingto settle, however, it is becoming apparent that thepath towards building upon such early IO successeswill be anything but straightforward. In the meantime,more traditional “non-IO” approaches continue togenerate therapeutic responses and revenues. Indeed,the recent successes of tumor-agnostic “basket” trialsserve as powerful reminders of the potential fortargeted therapies in the modern age. Pharmas arechoosing different lanes where they believe they canwin, with some shunning IO altogether while otherschoosing to go all-in with CAR-Ts, for example. Suchstrategies from bellwethers have an impact on howbiotech and investors approach their own decisions,both in terms of where to invest and how to positionthemselves for success. Join us as we explore thetrade-offs and implications of different positioning andpartnering strategies being employed by pharma,biotech, and investors in what promises to be animportant and exciting discussion for anyone lookingto win in the massive but incredibly crowded oncologymarket.

Participants

Moderator: Joel Sandler - Associate Principal, CelloHealth BioConsulting

Panelist: Soren Bregenholt - CBO, IO Biotech

Panelist: Emilio Erazo-Fischer - Deputy Head ofOncology BD&L, Boehringer Ingelheim

Panelist: Serge Sagodira - Head of Transactions,Debiopharm

BREAK AND BREATHE

16:05 - 16:25Extra Activity

Level 1, Schubert 3

EXTRA ACTIVITY: BREAK AND BREATHEEnhance your conference experience by using simplebreathing techniques, movement and light stretches inorder to charge your body and mind for better decisionmaking and more energy throughout the day.

The breath is a source of life. By practicing specialbreathing techniques, we can fight diseases, stimulatethe endocrine and autonomic nervous systems andpurify the blood. These breathing techniques aredesigned to make the body fit and to handle stress ineveryday life.

Open to all. No prerequisites required. Standing andseated (chair) positions only.

Power up partneringONE: Experienced



This session is for delegates familiar with partneringwho want to up their game. Best practices forcollaborating with colleagues, saving time, increasingresponse rates and acceptance rates will be discussedin terms of partneringONE, including new powerfeatures to support optimal partnering etiquette. Comeaway from the session with a clear understanding ofhow partneringONE can support your company tomaximize ROI from partnering, at this and futureevents.


Participants






BREAK AND BREATHE


Level 1, Schubert 3




Champagne reception


Level 0, Hall A

EBD Group, Booth #61

Evening Networking Reception


LOCATION:HOFBURG ViennaHeldenplatz 11010 Vienna

The Hofburg Vienna was the former winter residenceof the Habsburgs, and boasts 54 staircases, 19courtyards and 2,600 different rooms. The splendidCeremonial Hall, designed as a throne room forEmperor Franz II/I, is a symphony of shapes andcolors, along with the stunning Grand Staircase thatleads to the conference halls. The ceiling paintings arealso a breathtaking sight.

Ever since the Congress of Vienna in 1814/15, theHofburg has been a regular venue for prominentinternational meetings, like the legendary encounterbetween the Presidents of the USSR and the UnitedStates, Nikita Khrushchev and John F. Kennedy, in1961, or the signing of the SALT II Treaty by USPresident Jimmy Carter and Soviet President LeonidBrezhnev in 1979, or more recently the visit of PopeBenedict XVI in 2007. Hofburg Vienna can be calledEurope’s first address for international meetings.

17:00–19:00 Shuttle buses depart from theconference center to partner hotels.18:30–19:15 Shuttle buses depart from theconference center to the evening event.21:00–22:00 Shuttle buses depart from the eveningevent to all conference hotels.





TIME BUSINESS DE-VELOPMENT

COMPANYPRESENTA-TIONS

EXTRA ACTIV-ITY

MAIN AGEN-DA

NETWORKING PARTNERING PLENARY POWER UPPARTNER-INGONE

SPOTLIGHT THERAPEUTIC WORKSHOP 1 WORKSHOP 2

07:00 07:45 - Regis-tration andExhibitionOpen

07:45 - Conti-nental Break-fast

08:00

09:00 09:00 - Theperfect pitch:Do you havewhat it takesto win over in-vestors?

09:00 - EBDAcademyBuzz Session:Out-licensingpresenta-tions: One isnot enough

10:00 10:00 - One-to-one meet-ings

10:45 - Wel-come andOpening Re-marks

10:00 - Powerup partner-ingONE: Es-sentials (plusExperienced)

11:00 11:15 - Open-ing PlenaryDiscussion:Time to turnthe ship: Ex-ploring under-served thera-peutic areas

12:00 12:00 - Lun-cheon

SCHEDULEDAY 1 - 25/03/2019






EXTRA ACTIV-ITY

MAIN AGEN-DA



13:00 13:30 - Whowins the seatwhen invest-ing in Euro-pean biotechcompanies?

13:30 - Phar-ma CompanyPresentations

13:30 - Evolv-ing biophar-ma land-scape in theAsia-Pacific

13:30 -Emerging op-portunitiesfor invest-ment andpartnering in“metabesity”

14:00 14:45 - Art ofmultitrackdeal: Keys tomaximizingthe value ofyour compa-ny

14:45 - Prod-uct develop-ment andmarket ac-cess: Thetransforma-tionalchanges with-in China

14:45 -What’s NEXTin NASH?

15:00

16:00 16:00 - To-wards thesplendid city:Creatingworld-leadingbiotech com-panies in Eu-rope

16:05 -BREAK ANDBREATHE

16:35 -BREAK ANDBREATHE

16:30 - Powerup partner-ingONE: Ex-perienced

16:00 - Com-mercial op-portunitiesand chal-lenges in celland gene:The keys tosuccess

16:00 - Oncol-ogy position-ing and part-nering strate-gies: IO, non-IO, and every-thing in be-tween!

17:00 17:45 -Champagnereception







EXTRA ACTIV-ITY

MAIN AGEN-DA



18:00

19:00 19:00 -Evening Net-working Re-ception





RISE AND RUN


Meeting at:Vienna Marriott Hotel – Main LobbyParkring 12a1010 Vienna

Ease yourself into a busy second day at BIO-EuropeSpring with an early-morning run along some ofVienna's famous sites. The pace will be comfortableenough to chat, and runners of all levels are welcome.Bring hat and gloves for a cold morning, but we willcancel for very inclement weather.








Level 0, Hall A

One-to-one meetings


Level 0, Hall A

Please note: One-to-one meetings will take place allday depending on your partnering schedule.

New partnership and investment models

09:00 - 10:00Startup Spotlight


With the entrance of new partners and investors,startups are not limited to seeking out VC funding todrive growth. Startups are advancing their research bypartnering with patient advocacy groups, academia,innovation hubs, and other stakeholders. Instead oftraditional funding, new models where partners areproviding infrastructure, preclinical research supportfor stake in company, or expertise to offset costs aregaining momentum. Learn about the latest modelsand perhaps meet your match.

Participants

Moderator: Lucie Ellis - Executive Editor, In Vivo,Informa Pharma Intelligence

Panelist: Gabriela Apiou - Director of StrategicAlliances, Mass General Hospital Research Institute

Panelist: Borja Carsi - Investment Officer, EuropeanInvestment Bank

Panelist: Michael Johnson - VP Transactions,Immunology, Eli Lilly and Company

Panelist: Johannes Sarx - Managing Director,LISAvienna

Panelist: Marek Tyl - CEO and Founder, GlobalInnovation Forum

Company Presentations


Level 1, Schubert 4 & 5

Startup Spotlight Company Presentations



Presenting Companies:

Elypta AB

Medibiofarma

Ablevia biotech GmbH

Isanans Pharma

Respirogen, Inc.

Stimunity

ResoTher Pharma ApS

Stratify Genomics

GlakoLens

EsoCap AG

Aelian Biotechnology

ImStar Therapeutics

Participants

Coach: Julia Belaya - Director, Health and StartupCreasphere, Plug & Play

Coach: Tim Luker - VP, Emerging Technology andInnovation, Corporate Business Development, Eli Lilly &Company

Coach: Stefan Luzi - Partner, Gilde Healthcare

Coach: Daniel Parera - Executive-in-residence, TVMCapital Life Science

BREAK AND BREATHE


Level 1, Schubert 3








BREAK AND BREATHE


Level 1, Schubert 3




Luncheon



What a partner wants



Prior to the pitch, a startup must understand whatpotential partners and investors are looking for in theircompany. Why is your science relevant to a diseaseand how will you demonstrate your product claims?Who in your team has the experience to move aproduct through development and understand whenyou need outside help? What elements are obviousand what should companies be thinking about that’scurrently not on their radar?

Participants

Moderator: Giovanni Mariggi - Partner, Medicxi

Panelist: Julia Belaya - Director, Health and StartupCreasphere, Plug & Play

Panelist: Tim Haines - Managing Partner, Abingworth

Panelist: Julien Michaux - Managing Director, NorgineVentures

Panelist: Katja Rosenkranz - Partner, V-Bio Ventures

Panelist: Paul-Peter Tak - Venture Partner, FlagshipPioneering

Plenary Session: A day in the life ofexperienced dealmakers

13:00 - 14:00Plenary

Level 0, Lehar 3/4

Participants

Moderator: Evonne Sepsis - Founder and ManagingDirector, ESC Advisors

Moderator: Anton Gueth - Managing Director,EVOLUTION Life Science Partners

Panelist: Paul Biondi - Senior VP, Strategy andBusiness Development, Bristol-Myers Squibb

Panelist: Constantine Chinoporos - CBO, BostonPharmaceuticals

Panelist: Philippe Lopes-Fernandes - Senior VP, GlobalHead, Business Development and AllianceManagement, MERCK

Panelist: Chris Vlahos - Global Head, ExternalInnovation, Rare Diseases and Neuroscience, Ipsen




Case study: Following the clients' demand:Expanding from Europe to the US

14:00 - 15:00Additional Program

Level 1, Schubert 6

Having a global footprint paves the way to greaterbenefits, allowing for better coordination of resourcesand often surprising benefits for partners all along theproduction and supply chain. This session willexamine international case studies to show how thefollow-on effects of a new geographical base canimpact production, supply, strategy, and partnerrelationships. Panelists will also examine the factorsthat need to be considered before, during and after thetransaction in order to realize successful integration.

Participants

Moderator: Johannes Roebers - Founder and CEO,Cilatus Biopharma Consulting AG

Panelist: Klaus Maleck - CEO, TETEC AG

Panelist: Bernd Muehlenweg - CBO, Nanobiotix

Panelist: Konstantin Petropoulos - VP, BD, Marketingand Sales, Leukocare AG

Panelist: Federico Pollano - Senior VP, BusinessDevelopment, Rentschler Biopharma SE

Panelist: Marianne Spaene - Executive VP, GlobalBusiness Development, Marketing and Sales, SiegfriedAG

Pushing the boundaries: Digital technologiestransforming the biopharma value chain



There is little doubt that digital technology istransforming the entire biopharma value chain.Biopharma companies are using data analytics, bigdata, genomics, artificial intelligence and other digitaltechnologies to bolster research and development,facilitate regulatory approval, speed time to market,find new ways to connect with patients andconsumers, and measure the safety and effectivenessof therapies. This panel will dive into the opportunitiesand challenges that digital technologies present,exploring such questions as: What are the successfuluse cases for digital technologies in biopharma? Whatare the biggest challenges and risks? How can digitaltechnologies be applied to the biopharma sector?

Participants

Moderator: Martin Pöhlchen - Senior Partner, AliraHealth

Panelist: Etienne Bendjebbar - Business DevelopmentAssociate, OWKIN

Panelist: Sarah Hogan - Partner, McDermott Will &Emery LLP

Panelist: Nora Khaldi - Founder and CSO, Nuritas

Panelist: Bernd Nosse - Global Head BD&LTechnologies, Boehringer Ingelheim InternationalGmbH

Panelist: Andreas Posch - Managing Director and CEO,Ares Genetics











Participants


BREAK AND BREATHE


Level 1, Schubert 3




BREAK AND BREATHE


Level 1, Schubert 3




Exhibit Hall Hospitality Receptions


Evening Networking Reception


LOCATION:GösserhalleLaxenburgerstrasse 2B1100 Vienna

Over 120 years old, Gösserhalle once served as awarehouse for Gösser Bier (from Styria), which wasdelivered in wooden barrels to taverns around Viennaby horse-drawn carriages. The charming venue withsix architecturally unique spaces is a journey into OldWord ambience in the center of Vienna.

17:00–19:00 Shuttle buses depart from theconference center to partner hotels.18:30–19:15 Shuttle buses depart from theconference center to the evening event.21:30–23:00 Shuttle buses depart from the eveningevent to all conference hotels.





TIME ADDITIONALPROGRAM

COMPANY PRE-SENTATIONS

EXTRA ACTIVITY MAIN AGENDA NETWORKING PARTNERING PLENARY POWER UP PART-NERINGONE

SPOTLIGHT STARTUP SPOT-LIGHT

06:00 06:30 - RISE ANDRUN

07:00 07:45 - Registra-tion and Exhibi-tion Open

07:45 - Continen-tal Breakfast

08:00 08:00 - One-to-one meetings

09:00 09:00 - CompanyPresentations

09:00 - New part-nership and in-vestment models

10:00 10:00 - StartupSpotlight Compa-ny Presentations

11:00 11:05 - BREAKAND BREATHE

11:35 - BREAKAND BREATHE

12:00 12:00 - Luncheon 12:15 - What apartner wants

13:00 13:00 - PlenarySession: A day inthe life of experi-enced dealmak-ers







EXTRA ACTIVITY MAIN AGENDA NETWORKING PARTNERING PLENARY POWER UP PART-NERINGONE

SPOTLIGHT STARTUP SPOT-LIGHT

14:00 14:00 - Casestudy: Followingthe clients' de-mand: Expandingfrom Europe tothe US

14:00 - CompanyPresentations

14:15 - Pushingthe boundaries:Digital technolo-gies transform-ing the biophar-ma value chain

15:00

16:00 16:05 - BREAKAND BREATHE


16:00 - Power uppartneringONE:Essentials (plusExperienced)

17:00 17:45 - ExhibitHall HospitalityReceptions

18:00

19:00 19:00 - EveningNetworking Re-ception












Level 0, Hall A

One-to-one meetings


Level 0, Hall A

Gut instincts: Latest partnerships andcollaboration models in microbiome

09:00 - 10:00Spotlight on Microbiome

Level 1 Schubert 6

Gain insights to the different approaches and latestcollaboration models taking shape in the Microbiomearena.

Participants

Moderator: Philip Hemme - CEO, Labiotech.eu

Panelist: Michel de Baar - Executive Director, BusinessDevelopment, Europe, MSD

Panelist: Isabelle de Cremoux - CEO and ManagingPartner, Seventure Partners

Panelist: Georges Rawadi - CEO, LNC Therapeutics

HTA session/IGES: How does Europe set theprice for a new drug?



There is only one central approval for innovative drugsin Europe, but each European member state has itsown pricing system. Per capita income, social securitysystems and medical guidelines vary from state tostate. In this interactive workshop, we would like toexplain how the health economic value of innovativemedicines is assessed, how prices are determined andhow small and mid-sized companies deal best with theEuropean regulations and the different organizationsat stake. Smaller and mid-sized biopharma companiesare invited to join and discuss with the experts.

Participants

Moderator: Peter Braunhofer - Senior Expert, Valueand Access Europe, IGES Group, Basel

Panelist: Patrick Schneider - Senior Expert, Pricingand Market Access Switzerland, Hölzle, Buri & Partner,Zug

Panelist: Claudia Wild - Director, Ludwig BoltzmannInstitute for Health Technology Assessment, Vienna










Participants


Pre-Conference Workshop: Navigating theregulatory landscape for microbiometherapeutics


Part 1: What are the need-to-know regulatory,nonclinical and clinical-specific characteristics ofmicrobiome products?

Speakers:

Peri Aghadiuno – EU Medical Director, VoisinConsulting Life Sciences

Clara Desvignes – Regulatory Scientist, VoisinConsulting Life Sciences

Cécile Rousseau – Director, Voisin Consulting LifeSciences

This workshop is a pre-event taste of the MicrobiomeTherapeutics conference which takes place March28–29 here in Vienna, connecting the dots fromdiscovery to commercialization. See here for fullworkshop details for the two-day agenda Thursdayand Friday, March 28–29.





https://lifesciences.knect365.com/microbiome-therapeutics-europe/



BREAK AND BREATHE


Level 1, Schubert 3

Enhance your conference experience by using simplebreathing techniques, movement and light stretches inorder to charge your body and mind for better decisionmaking and more energy throughout the day. Thebreath is a source of life. By practicing specialbreathing techniques, we can fight diseases, stimulatethe endocrine and autonomic nervous systems andpurify the blood. These breathing techniques aredesigned to make the body fit and to handle stress ineveryday life. Open to all. No prerequisites required.Standing and seated (chair) positions only.

Power up partneringONE: Experienced



This session is for delegates familiar with partneringwho want to up their game. Best practices forcollaborating with colleagues, saving time, increasingresponse rates and acceptance rates will be discussedin terms of partneringONE, including new powerfeatures to support optimal partnering etiquette. Comeaway from the session with a clear understanding ofhow partneringONE can support your company tomaximize ROI from partnering, at this and futureevents.

This session is being offered multiple times duringBIO-Europe Spring. Each session is limited to 20people. Please reserve your seat by adding the sessionto your personal agenda. Or drop by the Power Zone,beside the partnering help desk, with any questions.

Participants


BREAK AND BREATHE


Level 1, Schubert 3

Enhance your conference experience by using simplebreathing techniques, movement and light stretches inorder to charge your body and mind for better decisionmaking and more energy throughout the day. Thebreath is a source of life. By practicing specialbreathing techniques, we can fight diseases, stimulatethe endocrine and autonomic nervous systems andpurify the blood. These breathing techniques aredesigned to make the body fit and to handle stress ineveryday life. Open to all. No prerequisites required.Standing and seated (chair) positions only.

Luncheon



Pre-Conference Workshop: Navigating theregulatory landscape for microbiometherapeutics


Part 2: What are the need-to-know regulatory,nonclinical and clinical-specific characteristics ofmicrobiome products?

Speakers:

Peri Aghadiuno – EU Medical Director, VoisinConsulting Life Sciences

Clara Desvignes – Regulatory Scientist, VoisinConsulting Life Sciences

Cécile Rousseau – Director, Voisin Consulting LifeSciences

This workshop is a pre-event taste of the MicrobiomeTherapeutics conference which takes place March28–29 here in Vienna, connecting the dots fromdiscovery to commercialization. See here for fullworkshop details for the two-day agenda Thursdayand Friday, March 28–29.

Session 1: The 5 most important upcomingtrends in European biotech

14:00 - 14:45Labiotech Refresh event


The CEO of Evotec will discuss his views on theupcoming trends and challenges facing Europeanbiotech in the next few years. This will be followed by adiscussion with Labiotech CEO Philip Hemme.

Participants

Moderator: Philip Hemme - CEO, Labiotech.eu

Speaker: Werner Lanthaler - CEO, Evotec

Buses to airport

14:00 - 18:00Transportation to Airport

Shuttle buses depart from the conference center toVienna Airport

Session 2: What's lying ahead for Europeanbiotech in 2019 and beyond

14:50 - 15:35Labiotech Refresh event


Helen Albert, Editor-in-Chief of Labiotech, will discussthe more immediate future of European biotech andwhat the hot topics in 2019 and beyond will be with apanel of three great speakers from both the scientificand the investment side of the industry.

Participants

Moderator: Helen Albert - Editor-in-Chief, Labiotech.eu

Panelist: Alexander Belcredi - CEO, PhagoMed

Panelist: Vanessa King - CEO, Virion Biotherapeutics

Panelist: Erich Tauber - CEO, Themis Bioscience

Baba (Goodbye) Vienna – Bienvenue à Paris!


Level 0, Hall A, Booth #50

Join us in Paris at BIO-Europe Spring 2020, March23–25, 2020










EXTRA ACTIVITY LABIOTECH RE-FRESH EVENT

MAIN AGENDA NETWORKING PARTNERING POWER UP PART-NERINGONE

SPOTLIGHT ONMICROBIOME

TRANSPORTA-TION TO AIRPORT

07:00 07:45 - Registra-tion and Exhibi-tion Open

07:45 - Continen-tal Breakfast

08:00 08:00 - One-to-one meetings

09:00 09:00 - HTA ses-sion/IGES: Howdoes Europe setthe price for anew drug?

09:30 - CompanyPresentations

09:30 - Power uppartneringONE:Essentials (plusExperienced)

09:00 - Gut in-stincts: Latestpartnerships andcollaborationmodels in micro-biome

10:00

11:00 11:00 - Pre-ConferenceWorkshop: Navi-gating the regu-latory landscapefor microbiometherapeutics



11:30 - Power uppartneringONE:Experienced

12:00 12:00 - Luncheon

13:00 13:00 - Pre-ConferenceWorkshop: Navi-gating the regu-latory landscapefor microbiometherapeutics







EXTRA ACTIVITY LABIOTECH RE-FRESH EVENT

MAIN AGENDA NETWORKING PARTNERING POWER UP PART-NERINGONE

SPOTLIGHT ONMICROBIOME

TRANSPORTA-TION TO AIRPORT

14:00 14:00 - Session1: The 5 mostimportant up-coming trends inEuropeanbiotech

14:50 - Session2: What's lyingahead for Euro-pean biotech in2019 and beyond

14:00 - Buses toairport

15:00

16:00 16:00 - Baba(Goodbye) Vien-na – Bienvenue àParis!





MICROBIOME THERAPEUTICS 28-29 March2019

09:00 - 19:00SIDE EVENT 1

Connecting The Dots From Discovery ToCommercialisation

Advance Your Translational Human MicrobiomeResearch, Clinical Trials, Emerging Technology,Manufacturing and Regulatory Acumen

28 - 29 March 2019

FIND OUT MORE

Vienna Biocenter Tour

09:00 - 13:30Site Tour 1

For BIO-Europe Spring attendees only: Trip to theVienna BioCenter

Make the most out of your stay in Vienna and join thisunique tour to one of Europe’s biggest life scienceshubs.

BIO-Europe Spring attendees have the chance to joinsite visits to learn more about Vienna’s life sciencecommunity. Winners of the Start Alliance program“Discover Vienna: Life Sciences”, operated incollaboration with the Vienna Business Agency, areespecially encouraged to make use of this greatopportunity.

The number of participants is limited. Registration ismandatory.

Click Here To Register

Trip to the Vienna BioCenter

Preliminary program

9:00 am – Bus pick up at Messe Wien

9:30 am – Welcome Valneva Austria GmbH

9:40 am – Vienna Business Agency and LISAvienna

10:00 am – Introduction Vienna BioCenter

10:20 am – Coffee break

10:40 am – Introduction Vienna BioCenter CoreFacilities

11:00 am – Campus tour

12:15 pm - Networking lunch with companies andinstitutes from Vienna Biocenter

1:30 pm - Bus back to Messe Wien

Boehringer Ingelheim Tour

09:00 - 13:30Site Tour 2

Boehringer Ingelheim invites you to tour itsfacility in Vienna on Thursday, March 28th

Boehringer Ingelheim, one of the world’s leadingcontract development and manufacturingorganizations for biopharmaceuticals invites you totour its facility in Vienna on Thursday, March 28th. Abus pick-up will be at Messe Vienna at 9:00 a.m.

This is a chance to explore and witness ourbiopharmaceutical manufacturing, highest qualitystandards and overall excellence. In addition, you willhave the opportunity to meet with site and technologyexperts, and discuss potential partnerships.

The guided tour of the Boehringer Ingelheim state-of-the-art facility will show you our core capabilities ascenter of excellence in process development andmanufacturing of biopharmaceuticals using microbialbased technologies.

With the currently ongoing constructions to establish alarge scale cell culture facility the site will be the onlymember in Boehringer Ingelheim’s biopharmaceuticalmanufacturing network offering variousmanufacturing technologies. Visitors will gain insightsinto both capabilities of Boehringer Ingelheim RCV. Formore information please visit www.boehringer-ingelheim.at

Following the tour and prior to returning by bus back toMesse Vienna at 01:30 pm, you will have the chance tofurther network over lunch.

Space is limited so RSVP today [email protected]!

SESSIONSPOST-EVENT PROGRAMS - 28/03/2019




https://lifesciences.knect365.com/microbiome-therapeutics-europe/?_ga=2.124197449.2138495466.1544127161-896449931.1527005484

https://www.lisavienna.at/events/detail/for-bio-europe-spring-attendees-only-trip-to-the-vienna-biocenter/

https://www.boehringer-ingelheim.at

https://www.boehringer-ingelheim.at

mailto:[email protected]

TIME SIDE EVENT 1 SITE TOUR 1 SITE TOUR 2

09:00 09:00 - MICROBIOME THERAPEUTICS28-29 March 2019

09:00 - Vienna Biocenter Tour 09:00 - Boehringer Ingelheim Tour

SCHEDULEPOST-EVENT PROGRAMS - 28/03/2019




sessions bio-europe springevents.ebdgroup.com/bes/core/downloads/2019/bes 2019 agenda.pdf · their...

Documents